Skip to content

ASPIRIN FOR PREVENTION OF CLOT FORMATION IN ACUTE SPINAL CORD INJURIES - A RANDOMIZED CONTROLLED TRIAL

ASPIRIN THROMBOPROPHYLAXIS FOR ACUTE SPINAL CORD INJURIES - A RANDOMIZED CONTROLLED TRIAL - ATASCI TRIAL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/01/002332
Enrollment
200
Registered
2012-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z77-Z99- Persons with potential health hazards related to family and personal history and certain conditions influencing health status

Interventions

Intervention1: Aspirin: Low dose (150 mg)aspirin (acetylsalicylic acid) administered once daily for a period of 90 days. Control Intervention1: Placebo: Placebo Tablets. Administered once daily for a

Sponsors

AOSpine Asia Pacific
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a)Patients with acute spinal cord injury (i.e those with neurological deficit) presenting within 7 days of injury. b)Age above 18 years and below 60 years of age.

Exclusion criteria

Exclusion criteria: a)Cases of spinal trauma without spinal cord injury i.e. patients without neurological deficit. b)Cases presenting after 7 days of injury. c)Age below 18 years or above 60 years. d)Pregnant patients. e)Past history of radiologically documented venous thromboembolism f)Cases with a beneficial and clear indication of aspirin use e.g. patients with Myocardial Infarction or those requiring long term antiplatelet therapy. g)Anticipated non-availability of follow-up and failure or inability to give informed consent. h)Cases with contraindications to aspirin use, viz. history of acid peptic disease or gastro-esophageal reflux disesase, history of bleeding disorders, hypoprothrombinemia or haemophilias, chronic renal disease or chronic liver disease, history of allergy to aspirin and history of bronchial asthma. i)Cases who have taken aspirin within 48 hours prior to admission j)Patients on long term treatment with NSAIDs.

Design outcomes

Primary

MeasureTime frame
a) Reduction in the risk of venous thromboembolism events and/or b) all cause mortality at the end of ninety days.Timepoint: 90 days

Secondary

MeasureTime frame
Occurence of major bleeds (i.e. those necessitating blood transfusion) and minor bleeds (i.e. those not necessitating blood transfusion)and other complications specifically related to aspirin.Timepoint: 90 days

Countries

India

Contacts

Public ContactDR SIDDHARTHA SHARMA

GOVERNMENT MEDICAL COLLEGE AND ASSOCIATED HOSPITALS, JAMMU

sids82@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026